Federal Register of Legislation - Australian Government

Primary content

PB 65 of 2019 Determinations/Health as made
This instrument amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) to increase the brand premium to multiple brands of pharmaceutical items in addition to removing four brands of four pharmaceutical items that will no longer be Pharmaceutical Benefits Scheme (PBS) listed on 1 August 2019.
Administered by: Health
Registered 30 Jul 2019
Tabling HistoryDate
Tabled HR31-Jul-2019
Tabled Senate01-Aug-2019
Date of repeal 14 Nov 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 65 of 2019

 

National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 7)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

 

Dated        26 July 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 


_________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 7).

(2)          This Instrument may also be cited as PB 65 of 2019.

2          Commencement

This Instrument commences on 1 August 2019.

3          Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

 


Schedule 1     Amendments

[1]   Schedule 1, entry for Atenolol

omit from the column headed “Claimed Price”:                       7.33        substitute:                13.58

[2]   Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 4 mg

omit from the column headed “Claimed Price”:                       6.65        substitute:                12.96

[3]   Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg

omit from the column headed “Claimed Price”:                       7.52        substitute:                13.82

[4]   Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg

omit from the column headed “Claimed Price”:                       10.06      substitute:                16.37

[5]   Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg

omit from the column headed “Claimed Price”:                       13.62      substitute:                17.17

[6]   Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg

omit from the column headed “Claimed Price”:                       10.34      substitute:                16.65

[7]   Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg

omit from the column headed “Claimed Price”:                       15.40      substitute:                17.35

[8]   Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg

omit from the column headed “Claimed Price”:                       15.76      substitute:                18.12

[9]   Schedule 1, entry for Citalopram

omit from the column headed “Claimed Price”:                       9.65        substitute:                11.15

[10] Schedule 1, entry for Erythromycin

omit:

 

Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL

Oral

E.E.S. 200

1

4.46

6.66

 

  Powder for oral liquid 400 mg (as      ethyl succinate) per 5 mL, 100 mL

Oral

E.E.S. Granules

1

5.68

7.90

[11] Schedule 1, entry for Escitalopram in the form Tablet 10 mg (as oxalate)

omit from the column headed “Claimed Price”:                       11.35      substitute:                12.85

[12] Schedule 1, entry for Escitalopram in the form Tablet 20 mg (as oxalate)

omit from the column headed “Claimed Price”:                       11.69      substitute:                13.19

[13] Schedule 1, entry for Hypromellose

omit:

 

Eye drops 3 mg per mL, 15 mL

Application to the eye

Genteal

1

3.12

7.15

[14] Schedule 1, entry for Ibuprofen

omit from the column headed “Claimed Price”:                       4.11        substitute:                4.58

[15] Schedule 1, entry for Lisinopril in the form Tablet 5 mg

omit from the column headed “Claimed Price”:                       5.51       substitute:                6.51

[16] Schedule 1, entry for Lisinopril in the form Tablet 10 mg

omit from the column headed “Claimed Price”:                       6.51       substitute:                7.51

[17] Schedule 1, entry for Lisinopril in the form Tablet 20 mg

omit from the column headed “Claimed Price”:                        7.29      substitute:                8.29

[18] Schedule 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 50 mg [Brand: Betaloc]

omit from the column headed “Claimed Price”:                        5.26      substitute:                9.66

[19] Schedule 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 100 mg

omit from the column headed “Claimed Price”:                        5.76      substitute:                10.16

[20] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg

omit from the column headed “Claimed Price”:                        6.85      substitute:                7.60

[21] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg

omit from the column headed “Claimed Price”:                        11.73    substitute:                12.46

[22] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg

omit from the column headed “Claimed Price”:                        7.26      substitute:                7.61

[23] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

omit from the column headed “Claimed Price”:                        12.13    substitute:                12.51

[24] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

omit from the column headed “Claimed Price”:                        13.55    substitute:                13.90

[25] Schedule 1, omit entry for Potassium chloride

[26] Schedule 1, entry for Propranolol in the form Tablet containing propranolol hydrochloride 10 mg [Brand: Inderal]

omit from the column headed “Claimed Price”:                          6.05    substitute:                10.45

[27] Schedule 1, entry for Propranolol in the form Tablet containing propranolol hydrochloride 40 mg [Brand: Inderal]

omit from the column headed “Claimed Price”:                          6.30    substitute:                10.70

[28] Schedule 1, entry for Salbutamol in the form Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)

omit from the column headed “Claimed Price”:                          5.10    substitute:                5.60